MICROVIABLE THERAPEUTICS
Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
NEWS
You can follow the latest news of MicroViable in this section
Microviable will be attending Drug Discovery Innovation Programme 2024
Microviable is excited to join 24th Drug Discovery Innovation Programme that will take place on [...]
Microviable receives best company award at Keiretsu Forum event
Last week we presented Microviable Therapeutics at the online investors chapter of Keiretsu Forum and [...]
Microviable participates in a research that has demonstrated that certain microbiota bacteria can be used as new probiotics to improve physical performance.
The work, led by a joint IPLA-University of Oviedo research group and the company Microviable [...]
CONTACT
Get in touch with us for any questions using the following contact form.